Serum anti-Müllerian hormone as a predictor of polycystic ovarian syndrome among women of reproductive age

Polycystic ovarian syndrome (PCOS) affects up to one-fifth of women of reproductive age and causes anovulatory subfertility. Some studies have recommended that an anti-Müllerian hormone (AMH) level greater than 3.8-5 ng/mL can be used for diagnosing PCOS. This study aims to analyse serum AMH levels...

Full description

Saved in:

Bibliographic Details
Published in:	BMC women's health 2022-05, Vol.22 (1), p.199-199, Article 199
Main Authors:	Butt, Muhammad Salman, Saleem, Javeria, Aiman, Sobia, Zakar, Rubeena, Sadique, Iftikhar, Fischer, Florian
Format:	Article
Language:	eng
Subjects:	Age groups Amenorrhea Androgens Anti-Mullerian Hormone Anti-Müllerian hormone Care and treatment Causes of Cross-Sectional Studies Data collection Diabetes Diagnosis Enzyme-linked immunosorbent assay Female Fertility Gynecology Health aspects Hirsutism Hormones Humans Insulin resistance Luteinizing Hormone Measurement Menstruation Menstruation disorders Metabolism Methods Morphology Ovaries PCOS Polycystic ovary syndrome Polycystic Ovary Syndrome - complications Polycystic Ovary Syndrome - diagnosis Population Risk factors Rotterdam criteria Sample size Sampling techniques Stein-Leventhal syndrome Ultrasonic imaging Vitamin deficiency Womens health
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Polycystic ovarian syndrome (PCOS) affects up to one-fifth of women of reproductive age and causes anovulatory subfertility. Some studies have recommended that an anti-Müllerian hormone (AMH) level greater than 3.8-5 ng/mL can be used for diagnosing PCOS. This study aims to analyse serum AMH levels among PCOS women of reproductive age to use AMH as a biomarker predictor along with other Rotterdam criteria. In this cross-sectional study, a total of 98 women visiting the fertility center of a private hospital in Lahore, Pakistan, were screened. Data were obtained from 51 PCOS newly diagnosed women aged 28.24 years (SD ± 4.84 years) meeting at least two of the Rotterdam criteria and specific inclusion criteria. Baseline variables, menstrual cycle length, ovarian morphology on ultrasound, hirsutism, sex hormones, gonadotropin, and serum AMH levels were analysed during the follicular phase (1-5 days) of the menstrual cycle. Serum AMH was measured by an enzyme-linked immunosorbent assay. A high serum AMH level (7.23 ± 4.67 ng/ml) was recorded with normal sex hormone levels. Women with oligo-/amenorrhea had a significant mean difference for luteinizing hormone (p = 0.02) and AMH levels (p = 0.03) when compared with women of normal menstrual cycle length. PCOS women with high AMH levels (≥ 3.9 ng/ml) showed a significant difference in ovarian morphology (p
ISSN:	1472-6874 1472-6874